Patents by Inventor Joe Fred NAGAMIZO
Joe Fred NAGAMIZO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240150316Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.Type: ApplicationFiled: September 14, 2023Publication date: May 9, 2024Inventors: Yalda BRAVO, Austin Chih-Yu CHEN, Jinyue DING, Robert GOMEZ, Heather LAM, Joe Fred NAGAMIZO, Renata Marcella OBALLA, David Andrew POWELL, Tao SHENG
-
Patent number: 11795156Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.Type: GrantFiled: June 23, 2022Date of Patent: October 24, 2023Assignee: TEMPEST THERAPEUTICS, INC.Inventors: Yalda Bravo, Austin Chih-Yu Chen, Jinyue Ding, Robert Gomez, Heather Lam, Joe Fred Nagamizo, Renata Marcella Oballa, David Andrew Powell, Tao Sheng
-
Patent number: 11738009Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.Type: GrantFiled: April 17, 2018Date of Patent: August 29, 2023Assignee: TEMPEST THERAPEUTICS, INC.Inventors: Yalda Bravo, Jason David Burch, Austin Chih-Yu Chen, Joe Fred Nagamizo
-
Publication number: 20230234943Abstract: Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds for inhibiting three prime repair exonuclease 1 (“TREX1”).Type: ApplicationFiled: June 25, 2021Publication date: July 27, 2023Inventors: Thomas Walter DUBENSKY, JR., Ryan C. CLARK, Justin ERNST, Garrick K. PACKARD, Brett BUSCH, Joe Fred NAGAMIZO, Biswajit KALITA, Athisayamani Jeyaraj DURAISWAMY
-
Patent number: 11638704Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g. controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.Type: GrantFiled: June 22, 2021Date of Patent: May 2, 2023Assignee: TEMPEST THERAPEUTICS, INC.Inventors: Yalda Bravo, Jason David Burch, Austin Chih-Yu Chen, Joe Fred Nagamizo
-
Publication number: 20230045612Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.Type: ApplicationFiled: June 23, 2022Publication date: February 9, 2023Inventors: Yalda BRAVO, Austin Chih-Yu CHEN, Jinyue DING, Robert GOMEZ, Heather LAM, Joe Fred NAGAMIZO, Renata Marcella OBALLA, David Andrew POWELL, Tao SHENG
-
Patent number: 11472789Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.Type: GrantFiled: October 14, 2020Date of Patent: October 18, 2022Assignee: TEMPEST THERAPEUTICS, INC.Inventors: Yalda Bravo, Austin Chih-Yu Chen, Jinyue Ding, Robert Gomez, Heather Lam, Joe Fred Nagamizo, Renata Marcella Oballa, David Andrew Powell, Tao Sheng
-
Patent number: 11440897Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.Type: GrantFiled: October 14, 2020Date of Patent: September 13, 2022Assignee: TEMPEST THERAPEUTICS, INC.Inventors: Yalda Bravo, Austin Chih-Yu Chen, Jinyue Ding, Robert Gomez, Heather Lam, Joe Fred Nagamizo, Renata Marcella Oballa, David Andrew Powell, Tao Sheng
-
Publication number: 20210387985Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g. controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.Type: ApplicationFiled: June 22, 2021Publication date: December 16, 2021Inventors: Yalda BRAVO, Jason David BURCH, Austin Chih-Yu CHEN, Joe Fred NAGAMIZO
-
Patent number: 11066405Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.Type: GrantFiled: May 21, 2020Date of Patent: July 20, 2021Assignee: TEMPEST THERAPEUTICS, INC.Inventors: Yalda Bravo, Jason David Burch, Austin Chih-Yu Chen, Joe Fred Nagamizo
-
Patent number: 10968201Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.Type: GrantFiled: April 17, 2019Date of Patent: April 6, 2021Assignee: TEMPEST THERAPEUTICS, INC.Inventors: Yalda Bravo, Austin Chih-Yu Chen, Jinyue Ding, Robert Gomez, Heather Lam, Joe Fred Nagamizo, Renata Marcella Oballa, David Andrew Powell, Tao Sheng
-
Publication number: 20210024491Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.Type: ApplicationFiled: October 14, 2020Publication date: January 28, 2021Inventors: Yalda BRAVO, Austin Chih-Yu CHEN, Jinyue DING, Robert GOMEZ, Heather LAM, Joe Fred NAGAMIZO, Renata Marcella OBALLA, David Andrew POWELL, Tao SHENG
-
Publication number: 20210008046Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.Type: ApplicationFiled: April 17, 2018Publication date: January 14, 2021Inventors: Yalda BRAVO, Jason David BURCH, Austin Chih-Yu CHEN, Joe Fred NAGAMIZO
-
Publication number: 20200283438Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.Type: ApplicationFiled: May 21, 2020Publication date: September 10, 2020Inventors: Yalda BRAVO, Jason David BURCH, Austin Chih-Yu CHEN, Joe Fred NAGAMIZO
-
Publication number: 20190315712Abstract: Compounds, compositions and methods are provided for modulating the activity of EP2 and EP4 receptors, and for the treatment, prevention and amelioration of one or more symptoms of diseases or disorders related to the activity of EP2 and EP4 receptors. In certain embodiments, the compounds are antagonists of both the EP2 and EP4 receptors.Type: ApplicationFiled: April 17, 2019Publication date: October 17, 2019Inventors: Yalda BRAVO, Austin Chih-Yu CHEN, Jinyue DING, Robert GOMEZ, Heather LAM, Joe Fred NAGAMIZO, Renata Marcella OBALLA, David Andrew POWELL, Tao SHENG